Search

Displaying results 4021 - 4030 of 9132 in total
  1. Drug

    Dichloroacetic acid

    go.drugbank.com/drugs/DB08809
    ApprovedInvestigationalWithdrawn

    DCA was approved for use in Canada in 1989 (as a topical formulation for treatment of warts and for cauterization and removal of a wide variety of skin and tissue lesions), but was cancelled post market … Salts of DCA are used as drugs since they inhibit the enzyme pyruvate dehydrogenase kinase.

  2. Drug

    Tezampanel

    go.drugbank.com/drugs/DB06354
    Investigational

    Tezampanel is an AMPA receptor antagonist.

  3. Drug

    CIGB 300

    go.drugbank.com/drugs/DB16464
    Investigational

    CIGB-300, is under investigation in clinical trials for its potential to treat various conditions, including NCT01639638 (recurrent and nonrecurrent condyloma) and NCT01639625 (squamous cell carcinoma and adenocarcinoma of the cervix)

  4. Drug

    Omacetaxine mepesuccinate

    go.drugbank.com/drugs/DB04865
    ApprovedInvestigationalWithdrawn

    Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies … Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species.

    Synonyms: 1-[(1S,3aR,14bS)-2-Methoxy-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[a][1,3]dioxolo[4,5-H]pyrrolo[2,1-b][3]benzazepin-1-yl] 4-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate
  5. Drug

    Idebenone

    go.drugbank.com/drugs/DB09081
    ApprovedInvestigational

    Idebenone is a synthetic analogue of ubiquinone (also known as Coenzyme Q10), a vital cell antioxidant and essential component of the Electron Transport Chain (ETC). … LHON is a mitochondrially inherited degeneration of retinal ganglion cells, resulting in acute central vision loss.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Ataluren

    go.drugbank.com/drugs/DB05016
    ApprovedWithdrawn

    Ataluren is a novel, orally administered drug that targets nonsense mutations. … More specifically, ataluren is used in the small group of patients whose disease is caused by a specific genetic defect (called a ‘nonsense mutation’) in the dystrophin gene.

  7. Drug

    Macitentan

    go.drugbank.com/drugs/DB08932
    ApprovedInvestigational

    Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH).[L35890] It was first approved by the FDA in 2013. … A combination product (Opsynvi) comprising macitentan and [tadalafil] was approved in Canada in October 2021 for the treatment of PAH.[L39105] It was subsequently approved by the FDA in March 2024.

    Categories: Endothelin A Receptor Antagonists
  8. Drug

    SR-123781A

    go.drugbank.com/drugs/DB05361
    Investigational

    SR-123781A is a synthetic hexadecasaccharide Factor IIa and Xa antagonist. It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).

  9. Drug

    Cardarine

    go.drugbank.com/drugs/DB05416
    Investigational

    Cardarine (GW-501516) is a peroxisome proliferator-activator receptor-delta agonist for the potential treatment of dyslipidemia.

  10. Drug

    AICA ribonucleotide

    go.drugbank.com/drugs/DB01700
    Investigational

    The drug was first used in the 1980s as a method to preserve blood flow to the heart during surgery and is currently of interest as a potential treatment for diabetes by increasing the metabolic activity … 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR) is an intermediate in the generation of inosine monophosphate and analog of adenosine monophosphate (AMP) that is capable of stimulating AMP-dependent